Emmanuel Hanon, Vicebio CEO
September 23, 2024 03:00 AM EDTUpdated 09:32 AM
Financing
Startups

UK vac­cine start­up Vice­bio snags $100M to take on GSK, Pfiz­er and Mod­er­na

Kyle LaHucik

Senior Reporter

The for­mer head of vac­cine R&D at GSK has pulled to­geth­er $100 mil­lion for a Lon­don-based biotech work­ing on res­pi­ra­to­ry vac­cines. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times